Pramipexole dihydrochloride

Modify Date: 2024-01-02 16:04:53

Pramipexole dihydrochloride structure	Common Name	Pramipexole dihydrochloride
	CAS Number	104632-25-9	Molecular Weight	284.249
	Density	N/A	Boiling Point	378ºC at 760 mmHg
	Molecular Formula	C₁₀H₁₉Cl₂N₃S	Melting Point	288-290ºC
	MSDS	USA	Flash Point	182.4ºC

Use of Pramipexole dihydrochloride

Pramipexole 2Hcl is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, D3, D4 receptor, respectively. IC50 Value: 3.9 nM(D2S); 2.2 nM(D2L); 0.5 nM(D3); 5.1 nM(D4)Target: Dopamine ReceptorPramipexole dihydrochloride is a dopamine receptor agonist with selectivity for the D3 receptor (Ki values are 3.9, 3.3, 0.5 and 3.9 nM for D2L, D2S, D3 and D4 receptors respectively). Pramipexole dihydrochloride exhibits negligable affinity for D1 and D5 receptors. Pramipexole has been found to have neuroprotective effects independent of its dopamine receptor agonism. It reduces mitochondrial reactive oxygen species (ROS) production and inhibits the activation of apoptotic pathways. Pramipexole displays activity in the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS).

Name	pramipexole hydrochloride anhydrous
Synonym	More Synonyms

Description	Pramipexole 2Hcl is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, D3, D4 receptor, respectively. IC50 Value: 3.9 nM(D2S); 2.2 nM(D2L); 0.5 nM(D3); 5.1 nM(D4)Target: Dopamine ReceptorPramipexole dihydrochloride is a dopamine receptor agonist with selectivity for the D3 receptor (Ki values are 3.9, 3.3, 0.5 and 3.9 nM for D2L, D2S, D3 and D4 receptors respectively). Pramipexole dihydrochloride exhibits negligable affinity for D1 and D5 receptors. Pramipexole has been found to have neuroprotective effects independent of its dopamine receptor agonism. It reduces mitochondrial reactive oxygen species (ROS) production and inhibits the activation of apoptotic pathways. Pramipexole displays activity in the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS).
Related Catalog	Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease
References	[1]. Mierau J, Schneider FJ, Ensinger HA et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36. [2]. El-Mallakh RS, Penagaluri P, Kantamneni A et al. Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review. Psychiatr Q. 2010 Sep;81(3):207-13. [3]. Perez-Lloret S, Rey MV, Ratti L, Rascol O. Pramipexole for the treatment of early Parkinson's disease. Expert Rev Neurother. 2011 Jul;11(7):925-35. [4]. Hametner EM, Seppi K, Poewe W. Pramipexole extended release in Parkinson's disease. Expert Rev Neurother. 2011 Sep;11(9):1229-34. [5]. Hametner EM, Seppi K, Poewe W. Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. Clin Interv Aging. 2012;7:83-8.

Description

Related Catalog

Signaling Pathways >> Autophagy >> Autophagy

Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor

Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor

Research Areas >> Neurological Disease

References

[1]. Mierau J, Schneider FJ, Ensinger HA et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36.

[2]. El-Mallakh RS, Penagaluri P, Kantamneni A et al. Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review. Psychiatr Q. 2010 Sep;81(3):207-13.

[3]. Perez-Lloret S, Rey MV, Ratti L, Rascol O. Pramipexole for the treatment of early Parkinson's disease. Expert Rev Neurother. 2011 Jul;11(7):925-35.

[4]. Hametner EM, Seppi K, Poewe W. Pramipexole extended release in Parkinson's disease. Expert Rev Neurother. 2011 Sep;11(9):1229-34.

[5]. Hametner EM, Seppi K, Poewe W. Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. Clin Interv Aging. 2012;7:83-8.

Boiling Point	378ºC at 760 mmHg
Melting Point	288-290ºC
Molecular Formula	C₁₀H₁₉Cl₂N₃S
Molecular Weight	284.249
Flash Point	182.4ºC
Exact Mass	283.067688
PSA	79.18000
LogP	4.15830
Vapour Pressure	6.49E-06mmHg at 25°C
Storage condition	Desiccate at RT

Hazard Codes	Xi
RIDADR	NONH for all modes of transport
HS Code	2934999090

(S)-pramipexole...

CAS#:943319-02-6

~84%

Pramipexole dih...

CAS#:104632-25-9

Literature: INSTYTUT FARMACEUTYCZNY Patent: WO2007/75095 A1, 2007 ; Location in patent: Page/Page column 7 ;

(6S)-2-Amino-6-...

CAS#:106006-84-2

~72%

Pramipexole dih...

CAS#:104632-25-9

Literature: Ravinder; Rajeswar Reddy; Panasa Reddy; Bandichhor, Rakeshwar Tetrahedron Letters, 2013 , vol. 54, # 36 p. 4908 - 4913

Pramipexole

CAS#:104632-26-0

~98%

Pramipexole dih...

CAS#:104632-25-9

Literature: Helm AG; CF Pharma Gyogyszergyarto Kft. Patent: EP1878731 A1, 2008 ; Location in patent: Page/Page column 11 ;

rac-cis-7-Hydro...

CAS#:1001648-71-0

~85%

Pramipexole dih...

CAS#:104632-25-9

Literature: Helm AG; CF Pharma Gyogyszergyarto Kft. Patent: EP1878731 A1, 2008 ; Location in patent: Page/Page column 11 ;

4,5,6,7-TETRAHY...

CAS#:106006-83-1

Pramipexole dih...

CAS#:104632-25-9